Clinical Trial Update: Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant Recipients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating eculizumab for thrombotic microangiopathy/atypical hemolytic uremic syndrome–associated multiple organ dysfunction synd…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atypical Hemolytic Uremic Syndrome
• Multiple Organ Dysfunction Syndrome
• Thrombotic Microangiopathies

Drugs mentioned

• Eculizumab (eculizumab)

Snippet

Sponsor: Children's Hospital Medical Center, Cincinnati | Conditions: Thrombotic Microangiopathies, Atypical Hemolytic Uremic Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2023-09-21